A detailed history of Vanguard Group Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 491,687 shares of ACXP stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
491,687
Previous 406,387 20.99%
Holding current value
$1.11 Million
Previous $1.56 Million 22.62%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.94 - $4.81 $165,482 - $410,292
85,300 Added 20.99%
491,687 $1.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.28 - $5.76 $364,983 - $1.64 Million
285,143 Added 235.18%
406,387 $1.56 Million
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.55 $282 - $509
200 Added 0.17%
121,244 $181,000
Q2 2023

Aug 14, 2023

BUY
$2.47 - $3.53 $77,950 - $111,403
31,559 Added 35.27%
121,044 $320,000
Q1 2023

May 15, 2023

BUY
$3.06 - $4.5 $273,824 - $402,682
89,485 New
89,485 $309,000

Others Institutions Holding ACXP

About Acurx Pharmaceuticals, Inc.


  • Ticker ACXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,556,600
  • Market Cap $26M
  • Description
  • Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...
More about ACXP
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.